Marie KoscoVilbois - AC Immune Chief Officer
| ACIU Stock | USD 2.68 0.02 0.74% |
Insider
Marie KoscoVilbois is Chief Officer of AC Immune
| Age | 66 |
| Address | Building B, Lausanne, Switzerland, 1015 |
| Phone | 41 21 345 91 21 |
| Web | https://www.acimmune.com |
AC Immune Management Efficiency
The company has return on total asset (ROA) of (0.1204) % which means that it has lost $0.1204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3116) %, meaning that it created substantial loss on money invested by shareholders. AC Immune's management efficiency ratios could be used to measure how well AC Immune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2024. Return On Capital Employed is likely to drop to -0.33 in 2024. Liabilities And Stockholders Equity is likely to gain to about 193.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 12.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Timothy MBA | Aerovate Therapeutics | 62 | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| James Goding | Opthea | N/A | |
| CPA MBA | Pharvaris BV | 63 | |
| Mike Zanoni | 4D Molecular Therapeutics | N/A | |
| Sanjay Chanda | AN2 Therapeutics | 59 | |
| Winston MBA | Pmv Pharmaceuticals | 48 | |
| Jon Voss | Abeona Therapeutics | 64 | |
| Arnold Levine | Pmv Pharmaceuticals | 84 | |
| Peter MD | Acrivon Therapeutics, Common | 61 | |
| Michael Gerometta | Opthea | 59 | |
| Fang PharmD | Black Diamond Therapeutics | 37 | |
| JD Esq | 4D Molecular Therapeutics | 73 | |
| MD MBA | 4D Molecular Therapeutics | 63 | |
| Eric Devroe | Acrivon Therapeutics, Common | 45 | |
| Annie Lee | Opthea | N/A | |
| Theresa Janke | 4D Molecular Therapeutics | 49 | |
| David Epstein | Black Diamond Therapeutics | 65 | |
Management Performance
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.12 |
AC Immune Leadership Team
Elected by the shareholders, the AC Immune's board of directors comprises two types of representatives: AC Immune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ACIU. The board's role is to monitor AC Immune's management team and ensure that shareholders' interests are well served. AC Immune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AC Immune's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nuno MD, Chief Officer | ||
| Christopher Roberts, Interim Fin | ||
| Sonia Poli, Head Science | ||
| Piergiorgio Donati, Chief Officer | ||
| Julian Snow, VP Development | ||
| Pr MD, Chief Officer | ||
| Joshua Drumm, Head Relations | ||
| JeanFabien Monin, Chief Administrative Officer | ||
| Howard Donovan, Chief Officer | ||
| Alexandre Caratsch, General Counsel | ||
| Gary Waanders, Senior Communications | ||
| Andrea Pfeifer, CEO CoFounder | ||
| Marie KoscoVilbois, Chief Officer | ||
| Judith Moore, Global Communications | ||
| Madiha Derouazi, Chief Officer | ||
| Joseph Wettstein, Head Officer | ||
| David Hickman, Head SME |
ACIU Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AC Immune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.97) % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 93.71 M | ||||
| Shares Outstanding | 98.94 M | ||||
| Shares Owned By Insiders | 21.68 % | ||||
| Shares Owned By Institutions | 28.80 % | ||||
| Number Of Shares Shorted | 1.02 M | ||||
| Price To Earning | (16.96) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.